BioRestorative Therapies, Inc.
$0.26
▼
-2.46%
2026-04-21 05:47:01
www.biorestorative.com
NCM: BRTX
Explore BioRestorative Therapies, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.72 M
Current Price
$0.26
52W High / Low
$2.04 / $0.19
Stock P/E
—
Book Value
$0.04
Dividend Yield
—
ROCE
-4386.1%
ROE
-3.2%
Face Value
—
EPS
$-1.58
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
0.27
Debt / Equity
11.85
Current Ratio
0.84
Quick Ratio
0.84
Forward P/E
-0.46
Price / Sales
17.04
Enterprise Value
$3.23 M
EV / EBITDA
-0.21
EV / Revenue
8.99
Rating
Strong Buy
Target Price
$15
EPS Forecast (FY)
—
Pros
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 2. | Definium Therapeutics, Inc. | $23.18 | — | $2.26 B | — | -44.54% | -64.06% | $23.41 / $5.36 | $3.36 |
| 3. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 4. | C4 Therapeutics, Inc. | $2.99 | — | $284.93 M | — | -32.05% | -44.44% | $3.82 / $1.09 | $2.65 |
| 5. | vTv Therapeutics Inc. | $37.75 | — | $157.78 M | — | -39.41% | -78.94% | $44 / $14 | $5.19 |
| 6. | Pelthos Therapeutics Inc. | $22.95 | — | $77.23 M | — | -31.06% | -2.4% | $54.29 / $9 | $12.02 |
| 7. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.02 M | 0.01 M | 0.3 M | 0.03 M | 0.04 M | — |
| Operating Profit | -3.83 M | -3.71 M | -3.31 M | -4.81 M | -2.69 M | — |
| Net Profit | -3.21 M | -3.04 M | -2.66 M | -5.34 M | -1.64 M | — |
| EPS in Rs | -0.13 | -0.12 | -0.1 | -0.21 | -0.06 | -0.13 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.36 M | 0.4 M | 0.15 M | 0.12 M |
| Operating Profit | -15.65 M | -11.56 M | -15.14 M | -18.86 M |
| Net Profit | -14.24 M | -8.98 M | -10.42 M | -13.22 M |
| EPS in Rs | -0.56 | -0.35 | -0.41 | -0.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.08 M | 12.28 M | 12.61 M | 16.43 M |
| Total Liabilities | 3.72 M | 3.75 M | 2.61 M | 6.14 M |
| Equity | 0.36 M | 8.53 M | 10 M | 10.29 M |
| Current Assets | 3.14 M | 11.14 M | 11.39 M | 15.13 M |
| Current Liabilities | 3.72 M | 3.75 M | 2.61 M | 5.98 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.79 M | -8.23 M | -6.43 M | -5.91 M |
| Investing CF | 8.9 M | 0.51 M | 3.25 M | -13.4 M |
| Financing CF | 2.85 M | 7.38 M | 2.35 M | 0 M |
| Free CF | -10.91 M | -8.34 M | -6.6 M | -6.35 M |
| Capex | -0.12 M | -0.11 M | -0.17 M | -0.44 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 175.03% | 21.7% | — | — |
| Earnings Growth % | 13.81% | 21.21% | — | — |
| Profit Margin % | -2239.25% | -7145.2% | -11036.97% | — |
| Operating Margin % | -2881.59% | -10382.33% | -15745.83% | — |
| Gross Margin % | 93% | 100% | — | — |
| EBITDA Margin % | -2834.45% | -10268.66% | -15645.21% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2021-10-27 | 1:0.00025 |